You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter to the editor
Effects of omalizumab in Aspergillus-associated airway disease
  1. L A Pérez-de-Llano1,
  2. M C Vennera2,
  3. A Parra3,
  4. J Guallar4,
  5. M Marin4,
  6. O Asensio5,
  7. P Ausin6,
  8. L Borderías7,
  9. C Fernández8,
  10. C Granel9,
  11. A Pérez-Pimiento10,
  12. M Rubio11
  1. 1Pneumology, Hospital Xeral-Calde, Lugo, Spain
  2. 2Pneumology and Respiratory Allergy, Hospital Clinic, CIBERES, Barcelona, Spain
  3. 3Allergology, Centro Hospitalario Universitario, Coruña, Spain
  4. 4Pneumology, Hospital General, Castellón, Spain
  5. 5Pediatry, Corporació Sanitaria Parc Tauli, Sabadell, Spain
  6. 6Pneumology, Hospital del Mar, Barcelona, Spain
  7. 7Pneumology, Hospital San Jorge, Huesca, Spain
  8. 8Allergology, Hospital 12 de Octubre, Madrid, Spain
  9. 9Allergology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  10. 10Allergology, Hospital Universitario Puerta del Hierro Majadahonda, Madrid, Spain
  11. 11Allergology, Hospital General Universitario Gregorio Marañon, Madrid, Spain
  1. Correspondence to Luis A Pérez de Llano, Pneumology Service, Hospital Xeral-Calde, c/Dr Ochoa, s/n, Lugo 27004, Spain; eremos26{at}hotmail.com

https://doi.org/10.1136/thx.2010.153312

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The clinical spectrum of Aspergillus-associated airway diseases (AAAD) includes Aspergillus-induced asthma, allergic bronchopulmonary aspergillosis (ABPA) and bronchocentric granulomatosis. Corticosteroids are almost always used to suppress the immunological response to the fungal antigens.1 Although there are no evidence-based alternative treatment options besides steroids, the well-known adverse effects of these drugs have prompted clinicians to look beyond this standard practice and several cases of ABPA patients with very positive outcomes after omalizumab therapy have been recently published.2–6

    We recruited 18 patients (13 women; mean age 49±17 years) with AAAD (2 of them had been previously diagnosed with cystic fibrosis) from 11 Spanish hospitals. All of them had been treated …

    View Full Text

    Footnotes

    • Funding LAPL, MCV and LB have received payment from Novartis Farmaceútica for lectures, consultancy and support for travelling to meetings. AP has received support from Novartis Farmaceútica for lectures and MR for travelling to meetings. JG, MM, OA, PA, CF, CG and AP-P have no conflicts of interest.

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.